At ENDO 2026, the annual meeting of the Endocrine Society, researchers reported that measuring adrenocorticotropic hormone ...

Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...

The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...

Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, in a deal that would expand the ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...

On Sunday at the Endocrine Society's Annual Meeting in Chicago, Danish biopharmaceutical company H. Lundbeck presented a result that endocrinologists tracking Cushing's disease drug development have ...

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a deal worth around $10.0bn. Crinetics is a global ...

Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex's portfolio - PALSONIFY, Crinetics' recently launched, first ...

Vertex Pharma has made the largest acquisition in its history, agreeing to buy Crinetics Pharma for around $10 billion in a ...

Crinetics Pharmaceuticals stock is a 'Buy' rating due to EU approval and strong initial U.S. uptake of Palsonify for ...

Vertex Pharmaceuticals Incorporated VRTX on Monday agreed to acquire Crinetics Pharmaceuticals Inc. CRNX for $85 per share in ...